Adage Capital Partners
TYRA icon

Adage Capital Partners’s Tyra Biosciences TYRA Stock Holding History

Adage Capital Partners’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200,000
Closed -$2.78M – 948
2024
Q4 		$2.78M Hold
200,000
– – ﹤0.01% 771
2024
Q3 		$4.7M Buy
+200,000
New +$4.2M 0.01% 723

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners's TYRA Position: Q1 2025 in Review

Adage Capital Partners sold out of Tyra Biosciences (TYRA) in Q1 2025, closing a stake of 200,000 shares — an estimated $2.78M sold.

Adage Capital Partners first reported a position in TYRA in Q3 2024 and held it in 2 quarters. The position peaked at $4.7M in Q3 2024. 117 funds tracked by Wall St. Rank hold TYRA as of Q1 2025.

  • Adage Capital Partners reported no remaining Tyra Biosciences position as of Q1 2025 after selling out during the quarter.
  • Adage Capital Partners sold 200,000 Tyra Biosciences shares in Q1 2025, an estimated $2.78M.
  • Adage Capital Partners first reported a position in Tyra Biosciences in Q3 2024 and held it in 2 quarters.
  • Adage Capital Partners's Tyra Biosciences position peaked at $4.7M in Q3 2024.
  • 117 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2025.

Based on Adage Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.